

Total financial statements

Third quarter and first nine months 2005 consolidated accounts, IFRS



CONSOLIDATED STATEMENT OF INCOME

Total

(unaudited)

| 3 rd quarter 2005 | 3 rd quarter 2004 | Amounts in millions of euros (1) | 9 months 2005 | 9 months 2004 |
|---------------------------------|---------------------------------|---|------------------|------------------|
| 38,414 | 32,296 | Sales | 103,226 | 88,400 |
| (5,206) | (6,925) | Excise taxes | (15,503) | (17,559) |
| 33,208 | 25,371 | Revenues from sales | 87,723 | 70,841 |
| (20,088) | (14,689) | Purchases, net of inventory variation | (49,874) | (39,857) |
| (4,416) | (4,240) | Other operating expenses | (14,552) | (13,903) |
| (113) | (81) | Unsuccessful exploration costs | (277) | (263) |
| (1,277) | (1,324) | Depreciation, depletion, and amortization of tangible assets | (3,776) | (3,826) |
| | | Operating income | | |
| (89) | (51) | Corporate | (254) | (253) |
| 7,403 | 5,088 | Business segments * | 19,498 | 13,245 |
| 7,314 | 5,037 | Total operating income | 19,244 | 12,992 |
| 31 | - | Other income | 73 | 146 |
| (63) | (147) | Other expense | (242) | (542) |
| (324) | (171) | Financial charge on debt | (875) | (535) |
| 257 | 145 | Financial income on cash and cash equivalents and equity securities | 658 | 431 |
| (67) | (26) | Cost of net debt | (217) | (104) |
| 100 | 92 | Other financial income | 304 | 281 |
| (79) | (54) | Other financial expense | (202) | (158) |
| (3,768) | (2,516) | Income taxes | (9,655) | (6,367) |
| 281 | 449 | Equity in income (loss) of affiliates | 897 | 1,083 |
| 3,749 | 2,835 | Consolidated net income | 10,202 | 7,331 |
| 3,645 | 2,763 | Group share ** | 9,932 | 7,137 |
| 104 | 72 | Minority interests and dividends on subsidiaries' redeemable preferred shares | 270 | 194 |
| 6.20 | 4.57 | Earnings per share (euros) *** | 16.78 | 11.72 |
| 6,346 | 4,498 | * Adjusted operating income from business segments | 17,339 | 12,107 |
| 3,044 | 2,279 | Adjusted net operating income from business segments | 8,807 | 6,414 |
| 3,126 | 2,365 | ** Adjusted net income | 8,951 | 6,496 |
| 5.32 | 3.91 | *** Adjusted earnings per share (euros) | 15.13 | 10.67 |

(1) Except for earnings per share

CONSOLIDATED BALANCE SHEET

Total

| | Amounts in millions of euros | | | |
|---|-----------------------------------|------------------------------|-------------------|-----------------------------------|
| | September 30, 2005 (unaudited) | June 30, 2005 (unaudited) | December 31, 2004 | September 30, 2004 (unaudited) |
| ASSETS | | | | |
| NON-CURRENT ASSETS | | | | |
| Intangible assets, net | 4,305 | 3,319 | 3,176 | 3,538 |
| Property, plant, and equipment, net | 39,264 | 38,290 | 34,906 | 35,675 |
| Equity affiliates : investments and loans | 12,167 | 11,927 | 10,680 | 8,449 |
| Other investments | 1,302 | 1,212 | 1,198 | 1,350 |
| Other non-current assets | 1,905 | 2,056 | 2,351 | 2,028 |
| Total non-current assets | 58,943 | 56,804 | 52,311 | 51,040 |
| CURRENT ASSETS | | | | |
| Inventories, net | 12,951 | 11,499 | 9,264 | 9,712 |
| Accounts receivable, net | 17,740 | 17,250 | 14,025 | 14,646 |
| Prepaid expenses and other current assets | 6,295 | 5,542 | 5,314 | 4,616 |
| Cash and cash equivalents | 14,989 | 13,577 | 3,860 | 12,541 |
| Total current assets | 51,975 | 47,868 | 32,463 | 41,515 |
| TOTAL ASSETS | 110,918 | 104,672 | 84,774 | 92,555 |
| LIABILITIES & SHAREHOLDERS' EQUITY | | | | |
| EQUITY | | | | |
| Common shares | 6,226 | 6,359 | 6,350 | 6,543 |
| Paid-in surplus and retained earnings | 37,882 | 36,397 | 31,717 | 32,279 |
| Cumulative translation adjustment | 998 | 920 | (1,429) | 233 |
| Treasury shares | (5,381) | (7,067) | (5,030) | (7,126) |
| SHAREHOLDERS' EQUITY - GROUP SHARE | 39,725 | 36,609 | 31,608 | 31,929 |
| Minority interest and subsidiaries' redeemable preferred shares | 1,015 | 708 | 810 | 1,105 |
| TOTAL EQUITY | 40,740 | 37,317 | 32,418 | 33,034 |
| LONG-TERM LIABILITIES | | | | |
| Deferred income taxes | 7,653 | 7,485 | 6,402 | 6,131 |
| Employee benefits | 3,574 | 3,609 | 3,607 | 3,785 |
| Other liabilities | 6,589 | 6,626 | 6,274 | 6,004 |
| Total long-term liabilities | 17,816 | 17,720 | 16,283 | 15,920 |
| LONG-TERM DEBT | | | | |
| | 12,778 | 11,485 | 9,773 | 10,694 |
| CURRENT LIABILITIES | | | | |
| Accounts payable | 13,473 | 12,721 | 11,672 | 12,010 |
| Other creditors and accrued liabilities | 14,061 | 12,507 | 11,148 | 10,816 |
| Short-term borrowings and bank overdrafts | 12,050 | 12,922 | 3,480 | 10,081 |
| Total current liabilities | 39,584 | 38,150 | 26,300 | 32,907 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 110,918 | 104,672 | 84,774 | 92,555 |

CONSOLIDATED STATEMENT OF CASH FLOW

Total

(unaudited)

| 3 rd quarter 2005 | 3 rd quarter 2004 | Amounts in millions of euros | 9 months 2005 | 9 months 2004 |
|---|---------------------------------|---|------------------|------------------|
| CASH FLOW FROM OPERATING ACTIVITIES | | | | |
| 3,749 | 2,835 | Consolidated net income | 10,202 | 7,331 |
| 1,315 | 1,397 | Depreciation, depletion, and amortization | 3,915 | 4,007 |
| 206 | 192 | Long-term liabilities, valuation allowances, and deferred taxes | 1,070 | 419 |
| - | - | Impact of coverage of pension benefit plans | - | - |
| 113 | 81 | Unsuccessful exploration costs | 277 | 263 |
| (31) | 4 | (Gains)/Losses on sales of assets | (73) | (142) |
| (159) | (358) | Equity in income of affiliates (in excess of)/less than dividends received | (335) | (562) |
| 27 | 134 | Other changes, net | 70 | 245 |
| 5,220 | 4,285 | Cash flow from operating activities before changes in working capital | 15,126 | 11,561 |
| (456) | (210) | (Increase)/Decrease in operating assets and liabilities | (3,628) | (721) |
| 4,764 | 4,075 | CASH FLOW FROM OPERATING ACTIVITIES (1) | 11,498 | 10,840 |
| CASH FLOW USED IN INVESTING ACTIVITIES | | | | |
| (2,178) | (1,688) | Intangible assets and property, plant, and equipment additions | (5,674) | (4,596) |
| (84) | (80) | Exploration expenditures charged to expenses | (223) | (238) |
| (903) | (28) | Acquisitions of subsidiaries, net of cash acquired | (903) | (37) |
| (62) | (19) | Investments in equity affiliates and other securities | (134) | (108) |
| (130) | (152) | Increase in long-term loans | (462) | (596) |
| (3,357) | (1,967) | Investments | (7,396) | (5,575) |
| 31 | 28 | Proceeds from sale of intangible assets and property, plant, and equipment | 225 | 171 |
| - | - | Proceeds from sale of subsidiaries, net of cash sold | 11 | 1 |
| 69 | 8 | Proceeds from sale of non-current investments | 112 | 49 |
| 148 | 149 | Repayment of long-term loans | 490 | 317 |
| 248 | 185 | Total divestitures | 838 | 538 |
| (3,109) | (1,782) | CASH FLOW USED IN INVESTING ACTIVITIES | (6,558) | (5,037) |
| CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Issuance and repayment of shares: | | | | |
| 9 | - | Parent company's shareholders | 9 | 371 |
| (655) | (655) | Purchase of treasury shares | (2,674) | (2,563) |
| 8 | 36 | Minority shareholders | 79 | 118 |
| - | - | Subsidiaries' redeemable preferred shares | (156) | - |
| Cash dividends paid: | | | | |
| - | - | - Parent company's shareholders | (1,765) | (2,853) |
| - | (4) | - Minority shareholders | (152) | (145) |
| 1,197 | 460 | Net issuance/(repayment) of long-term debt | 2,235 | 1,700 |
| (759) | (680) | Increase/(Decrease) in short-term borrowings and bank overdrafts | 7,433 | 5,189 |
| - | 1 | Other changes, net | (1) | (2) |
| (200) | (842) | CASH FLOW FROM FINANCING ACTIVITIES | 5,008 | 1,815 |
| 1,455 | 1,451 | Net increase/decrease in cash and cash equivalents | 9,948 | 7,618 |
| (43) | (236) | Effect of exchange rates and changes in reporting entity on cash and cash equivalents | 1,181 | 63 |
| 13,577 | 11,326 | Cash and cash equivalents at the beginning of the period | 3,860 | 4,860 |
| 14,989 | 12,541 | CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 14,989 | 12,541 |

(1) Including payments relating to the Toulouse AZF plant explosion, offset by a long-term liability write-back of 14 million euros for the third quarter 2005, 65 million euros for the first nine months 2005.

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Total

(unaudited)

| (Amounts in millions of euros) | Common shares issued | | Paid-in surplus and retained earnings | Cumulative translation adjustment | Treasury shares | | Shareholders' equity | Subsidiaries' redeemable preferred shares | Minority interest | Total equity |
|--|----------------------|--------------|---------------------------------------|-----------------------------------|---------------------|----------------|----------------------|---|-------------------|---------------|
| | Number | Amount | | | Number | Amount | | | | |
| As of January 1, 2004 (French GAAP) | 649,118,236 | 6,491 | 30,408 | (3,268) | (26,256,899) | (3,225) | 30,406 | 396 | 664 | 31,466 |
| IFRS adjustments | - | - | (3,048) | 3,268 | (10,855,206) | (1,388) | (1,168) | - | 19 | (1,149) |
| As of January 1, 2004 (IFRS) | 649,118,236 | 6,491 | 27,360 | - | (37,112,105) | (4,613) | 29,238 | 396 | 683 | 30,317 |
| Cash dividend | - | - | (2,853) | - | - | - | (2,853) | - | (145) | (2,998) |
| Net income for the first nine months | - | - | 7,137 | - | - | - | 7,137 | 1 | 193 | 7,331 |
| Issuance of shares | 5,195,630 | 52 | 445 | - | - | - | 497 | - | - | 497 |
| Purchase of treasury shares | - | - | - | - | (16,500,000) | (2,563) | (2,563) | - | - | (2,563) |
| Cancellation of repurchased shares | - | - | - | - | - | - | - | - | - | - |
| Sale of treasury shares (1) | - | - | 11 | - | 583,981 | 50 | 61 | - | - | 61 |
| Translation adjustments | - | - | - | 233 | - | - | 233 | 6 | 9 | 248 |
| Other (2) | - | - | 179 | - | - | - | 179 | - | (38) | 141 |
| As of September 30, 2004 | 654,313,866 | 6,543 | 32,279 | 233 | (53,028,124) | (7,126) | 31,929 | 403 | 702 | 33,034 |
| Cash dividend | - | - | (1,440) | - | - | - | (1,440) | - | (62) | (1,502) |
| Net income for the last quarter | - | - | 3,731 | - | - | - | 3,731 | 5 | 82 | 3,818 |
| Issuance of shares | 575,174 | 6 | 33 | - | - | - | 39 | - | - | 39 |
| Purchase of treasury shares | - | - | - | - | (6,050,000) | (991) | (991) | - | - | (991) |
| Cancellation of repurchased shares | (19,873,932) | (199) | (2,877) | - | 19,873,932 | 3,076 | - | - | - | - |
| Sale of treasury shares (1) | - | - | 3 | - | 131,705 | 11 | 14 | - | - | 14 |
| Translation adjustments | - | - | - | (1,662) | - | - | (1,662) | (20) | (28) | (1,710) |
| Repayment of subsidiaries' redeemable preferred shares | - | - | - | - | - | - | - | (241) | - | (241) |
| Other (2) | - | - | (12) | - | - | - | (12) | - | (31) | (43) |
| As of December 31, 2004 (IFRS) | 635,015,108 | 6,350 | 31,717 | (1,429) | (39,072,487) | (5,030) | 31,608 | 147 | 663 | 32,418 |
| Cash dividend | - | - | (1,765) | - | - | - | (1,765) | - | (152) | (1,917) |
| Net income for the first nine months | - | - | 9,932 | - | - | - | 9,932 | 1 | 269 | 10,202 |
| Issuance of shares | 1,076,359 | 11 | 77 | - | - | - | 88 | - | - | 88 |
| Purchase of treasury shares | - | - | - | - | (15,693,500) | (2,927) | (2,927) | - | - | (2,927) |
| Cancellation of repurchased shares | (13,527,578) | (135) | (2,248) | - | 13,527,578 | 2,383 | - | - | - | - |
| Sale of treasury shares (1) | - | - | 30 | - | 1,774,063 | 193 | 223 | - | - | 223 |
| Repayment of subsidiaries' redeemable preferred shares | - | - | - | - | - | - | - | (156) | - | (156) |
| Translation adjustments | - | - | - | 2,427 | - | - | 2,427 | 8 | 49 | 2,484 |
| Other (2) | - | - | 139 | - | - | - | 139 | - | 186 | 325 |
| As of September 30, 2005 | 622,563,889 | 6,226 | 37,882 | 998 | (39,464,346) | (5,381) | 39,725 | - | 1,015 | 40,740 |

(1) Treasury shares related to the stock option purchase plans

(2) Mainly due to the charge related to stock options

BUSINESS SEGMENT INFORMATION

Total

(unaudited)

Amounts in millions of euros

| 3 rd quarter 2005 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|--------------|-------------|----------------|---------------|
| Non-Group sales | 5,065 | 27,936 | 5,401 | 12 | | 38,414 |
| Intersegment sales | 5,543 | 1,171 | 265 | 30 | (7,009) | - |
| Excise taxes | - | (5,206) | - | - | - | (5,206) |
| Revenues from sales | 10,608 | 23,901 | 5,666 | 42 | (7,009) | 33,208 |
| Operating expenses | (4,592) | (21,697) | (5,214) | (123) | 7,009 | (24,617) |
| Depreciation, depletion, and amortization of tangible assets | (817) | (265) | (187) | (8) | | (1,277) |
| Operating income | 5,199 | 1,939 | 265 | (89) | | 7,314 |
| Equity in income (loss) of affiliates and other items | 140 | 67 | 8 | 55 | | 270 |
| Tax on net operating income | (3,137) | (640) | (74) | 61 | | (3,790) |
| Net operating income | 2,202 | 1,366 | 199 | 27 | | 3,794 |
| Net cost of net debt | | | | | | (45) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (104) |
| Net income | | | | | | 3,645 |

| 3 rd quarter 2005 (adjustments) (*) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|--------------|--------------|--------------|
| Non-Group sales | | | | | | |
| Intersegment sales | | | | | | |
| Excise taxes | | | | | | |
| Revenues from sales | | | | | | |
| Operating expenses | - | 958 | 99 | - | | 1,057 |
| Depreciation, depletion, and amortization of tangible assets | - | - | - | - | | - |
| Operating income (1) | - | 958 | 99 | - | | 1,057 |
| Equity in income (loss) of affiliates and other items (2) | - | 18 | (5) | (200) | | (187) |
| Tax on net operating income | - | (316) | (31) | - | | (347) |
| Net operating income (1) | - | 660 | 63 | (200) | | 523 |
| Net cost of net debt | | | | | | - |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (4) |
| Net income | | | | | | 519 |

(*) Adjustments include special items, inventory valuation effect and equity share of amortization of intangible assets related to the Sanofi-Aventis merger

(1) Of which inventory valuation effect

On operating income

- 958 108 -

On net operating income

- 660 74 -

(2) Of which equity share of amortization of intangible assets related to the Sanofi-Aventis merger

- - - (112)

| 3 rd quarter 2005 (adjusted) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|--------------|-------------|----------------|---------------|
| Non-Group sales | 5,065 | 27,936 | 5,401 | 12 | | 38,414 |
| Intersegment sales | 5,543 | 1,171 | 265 | 30 | (7,009) | - |
| Excise taxes | - | (5,206) | - | - | - | (5,206) |
| Revenues from sales | 10,608 | 23,901 | 5,666 | 42 | (7,009) | 33,208 |
| Operating expenses | (4,592) | (22,655) | (5,313) | (123) | 7,009 | (25,674) |
| Depreciation, depletion, and amortization of tangible assets | (817) | (265) | (187) | (8) | | (1,277) |
| Operating income | 5,199 | 981 | 166 | (89) | | 6,257 |
| Equity in income (loss) of affiliates and other items | 140 | 49 | 13 | 255 | | 457 |
| Tax on net operating income | (3,137) | (324) | (43) | 61 | | (3,443) |
| Net operating income | 2,202 | 706 | 136 | 227 | | 3,271 |
| Net cost of net debt | | | | | | (45) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (100) |
| Net income | | | | | | 3,126 |

| 3 rd quarter 2005 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|-----------|--------------|-------|
| Total expenditures | 2,589 | 493 | 275 | - | - | 3,357 |
| Divestitures at selling price | 161 | 21 | - | 66 | - | 248 |
| Cash flow from operating activities (3) | 2,818 | 893 | 498 | 555 | - | 4,764 |

(3) In the Chemicals segment, this figure amounts to 512 million euros excluding 14 million euros paid relating to the Toulouse AZF plant explosion.

BUSINESS SEGMENT INFORMATION

Total

(unaudited)

Amounts in millions of euros

| 3 rd quarter 2004 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|--------------|---------------|--------------|-------------|----------------|---------------|
| Non-Group sales | 3,610 | 23,453 | 5,228 | 5 | | 32,296 |
| Intersegment sales | 3,984 | 838 | 220 | 75 | (5,117) | - |
| Excise taxes | | (6,925) | | | | (6,925) |
| Revenues from sales | 7,594 | 17,366 | 5,448 | 80 | (5,117) | 25,371 |
| Operating expenses | (3,295) | (15,872) | (4,838) | (122) | 5,117 | (19,010) |
| Depreciation, depletion, and amortization of tangible assets | (870) | (246) | (199) | (9) | | (1,324) |
| Operating income | 3,429 | 1,248 | 411 | (51) | | 5,037 |
| Equity in income (loss) of affiliates and other items | 129 | 29 | (23) | 205 | | 340 |
| Tax on net operating income | (2,019) | (401) | (124) | 16 | | (2,528) |
| Net operating income | 1,539 | 876 | 264 | 170 | | 2,849 |
| Net cost of net debt | | | | | | (14) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (72) |
| Net income | | | | | | 2,763 |

| 3 rd quarter 2004 (adjustments) (*) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|-----------|--------------|------------|
| Non-Group sales | | | | | | |
| Intersegment sales | | | | | | |
| Excise taxes | | | | | | |
| Revenues from sales | | | | | | |
| Operating expenses | - | 500 | 90 | - | | 590 |
| Depreciation, depletion, and amortization of tangible assets | - | - | - | - | | - |
| Operating income (1) | - | 500 | 90 | - | | 590 |
| Equity in income (loss) of affiliates and other items (2) | - | 17 | (19) | - | | (2) |
| Tax on net operating income | - | (165) | (23) | - | | (188) |
| Net operating income (1) | - | 352 | 48 | - | | 400 |
| Net cost of net debt | | | | | | - |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (2) |
| Net income | | | | | | 398 |

(*) Adjustments include special items, inventory valuation effect and equity share of amortization of intangible assets related to the Sanofi-Aventis merger

(1) Of which inventory valuation effect

| | | | | | | |
|-------------------------|---|-----|----|---|--|--|
| On operating income | - | 500 | 90 | - | | |
| On net operating income | - | 352 | 58 | - | | |

(2) Of which equity share of amortization of intangible assets related to the Sanofi-Aventis merger

| 3 rd quarter 2004 (adjusted) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|--------------|---------------|--------------|-------------|----------------|---------------|
| Non-Group sales | 3,610 | 23,453 | 5,228 | 5 | | 32,296 |
| Intersegment sales | 3,984 | 838 | 220 | 75 | (5,117) | - |
| Excise taxes | | (6,925) | | | | (6,925) |
| Revenues from sales | 7,594 | 17,366 | 5,448 | 80 | (5,117) | 25,371 |
| Operating expenses | (3,295) | (16,372) | (4,928) | (122) | 5,117 | (19,600) |
| Depreciation, depletion, and amortization of tangible assets | (870) | (246) | (199) | (9) | | (1,324) |
| Operating income | 3,429 | 748 | 321 | (51) | | 4,447 |
| Equity in income (loss) of affiliates and other items | 129 | 12 | (4) | 205 | | 342 |
| Tax on net operating income | (2,019) | (236) | (101) | 16 | | (2,340) |
| Net operating income | 1,539 | 524 | 216 | 170 | | 2,449 |
| Net cost of net debt | | | | | | (14) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (70) |
| Net income | | | | | | 2,365 |

| 3 rd quarter 2004 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|-----------|--------------|-------|
| Total expenditures | 1,385 | 376 | 211 | (5) | | 1,967 |
| Divestitures at selling price | 114 | 45 | 19 | 7 | | 185 |
| Cash flow from operating activities (3) | 2,269 | 852 | 300 | 654 | | 4,075 |

(3) In the Chemicals segment, this figure amounts to 365 million euros excluding 65 million euros paid relating to the Toulouse AZF plant explosion.

BUSINESS SEGMENT INFORMATION

Total

(unaudited)

Amounts in millions of euros

| 9 months 2005 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|---------------|--------------|-----------------|---------------|
| Non-Group sales | 14,080 | 72,471 | 16,655 | 20 | | 103,226 |
| Intersegment sales | 13,936 | 3,135 | 911 | 108 | (18,090) | - |
| Excise taxes | | (15,503) | | | | (15,503) |
| Revenues from sales | 28,016 | 60,103 | 17,566 | 128 | (18,090) | 87,723 |
| Operating expenses | (12,184) | (54,390) | (15,861) | (358) | 18,090 | (64,703) |
| Depreciation, depletion, and amortization of tangible assets | (2,411) | (784) | (557) | (24) | | (3,776) |
| Operating income | 13,421 | 4,929 | 1,148 | (254) | - | 19,244 |
| Equity in income (loss) of affiliates and other items | 393 | 294 | (105) | 248 | | 830 |
| Tax on net operating income | (7,917) | (1,641) | (311) | 142 | | (9,727) |
| Net operating income | 5,897 | 3,582 | 732 | 136 | | 10,347 |
| Net cost of net debt | | | | | | (145) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (270) |
| Net income | | | | | | 9,932 |

| 9 months 2005 (adjustments) (*) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|--------------|-------------|--------------|--------------|--------------|
| Non-Group sales | | | | | | |
| Intersegment sales | | | | | | |
| Excise taxes | | | | | | |
| Revenues from sales | | | | | | |
| Operating expenses | - | 2,113 | 57 | - | | 2,170 |
| Depreciation, depletion, and amortization of tangible assets | - | - | (11) | - | | (11) |
| Operating income (1) | - | 2,113 | 46 | - | | 2,159 |
| Equity in income (loss) of affiliates and other items (2) | - | 48 | (139) | (414) | | (505) |
| Tax on net operating income | - | (696) | 32 | - | | (664) |
| Net operating income (1) | - | 1,465 | (61) | (414) | | 990 |
| Net cost of net debt | | | | | | - |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (9) |
| Net income | | | | | | 981 |

(*) Adjustments include special items, inventory valuation effect and equity share of amortization of intangible assets related to the Sanofi-Aventis merger

(1) Of which inventory valuation effect

| | | | | | | |
|-------------------------|---|-------|----|---|--|--|
| On operating income | - | 2,113 | 66 | - | | |
| On net operating income | - | 1,465 | 48 | - | | |

(2) Of which equity share of amortization of intangible assets related to the Sanofi-Aventis merger

| 9 months 2005 (adjusted) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|---------------|--------------|-----------------|---------------|
| Non-Group sales | 14,080 | 72,471 | 16,655 | 20 | | 103,226 |
| Intersegment sales | 13,936 | 3,135 | 911 | 108 | (18,090) | - |
| Excise taxes | | (15,503) | | | | (15,503) |
| Revenues from sales | 28,016 | 60,103 | 17,566 | 128 | (18,090) | 87,723 |
| Operating expenses | (12,184) | (56,503) | (15,918) | (358) | 18,090 | (66,873) |
| Depreciation, depletion, and amortization of tangible assets | (2,411) | (784) | (546) | (24) | | (3,765) |
| Operating income | 13,421 | 2,816 | 1,102 | (254) | | 17,085 |
| Equity in income (loss) of affiliates and other items | 393 | 246 | 34 | 662 | | 1,335 |
| Tax on net operating income | (7,917) | (945) | (343) | 142 | | (9,063) |
| Net operating income | 5,897 | 2,117 | 793 | 550 | | 9,357 |
| Net cost of net debt | | | | | | (145) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (261) |
| Net income | | | | | | 8,951 |

| 9 months 2005 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|-----------|--------------|--------|
| Total expenditures | 5,590 | 1,069 | 678 | 59 | | 7,396 |
| Divestitures at selling price | 551 | 124 | 30 | 133 | | 838 |
| Cash flow from operating activities (3) | 7,737 | 2,512 | 785 | 464 | | 11,498 |

(3) In the Chemicals segment, this figure amounts to 850 million euros excluding 65 million euros paid relating to the Toulouse AZF plant explosion.

BUSINESS SEGMENT INFORMATION

Total

(unaudited)

Amounts in millions of euros

| 9 months 2004 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|---------------|--------------|-----------------|---------------|
| Non-Group sales | 10,853 | 62,725 | 14,797 | 25 | | 88,400 |
| Intersegment sales | 10,416 | 2,034 | 511 | 128 | (13,089) | - |
| Excise taxes | | (17,559) | | | | (17,559) |
| Revenues from sales | 21,269 | 47,200 | 15,308 | 153 | (13,089) | 70,841 |
| Operating expenses | (9,409) | (43,498) | (13,825) | (380) | 13,089 | (54,023) |
| Depreciation, depletion, and amortization of tangible assets | (2,444) | (744) | (612) | (26) | | (3,826) |
| Operating income | 9,416 | 2,958 | 871 | (253) | | 12,992 |
| Equity in income (loss) of affiliates and other items | 394 | 125 | (211) | 502 | | 810 |
| Tax on net operating income | (5,356) | (934) | (204) | 95 | | (6,399) |
| Net operating income | 4,454 | 2,149 | 456 | 344 | | 7,403 |
| Net cost of net debt | | | | | | (72) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (194) |
| Net income | | | | | | 7,137 |

| 9 months 2004 (adjustments) (*) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-------------|-----------|--------------|--------------|
| Non-Group sales | | | | | | |
| Intersegment sales | | | | | | |
| Excise taxes | | | | | | |
| Revenues from sales | | | | | | |
| Operating expenses | - | 936 | 202 | - | | 1,138 |
| Depreciation, depletion, and amortization of tangible assets | - | - | - | - | | - |
| Operating income (1) | - | 936 | 202 | - | | 1,138 |
| Equity in income (loss) of affiliates and other items (2) | - | 29 | (220) | - | | (191) |
| Tax on net operating income | - | (309) | 7 | - | | (302) |
| Net operating income (1) | - | 656 | (11) | - | | 645 |
| Net cost of net debt | | | | | | - |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (4) |
| Net income | | | | | | 641 |

(*) Adjustments include special items, inventory valuation effect and equity share of amortization of intangible assets related to the Sanofi-Aventis merger

(1) Of which inventory valuation effect

| | | | | | | |
|-------------------------|---|-----|-----|---|--|--|
| On operating income | - | 936 | 202 | - | | |
| On net operating income | - | 656 | 133 | - | | |

(2) Of which equity share of amortization of intangible assets related to the Sanofi-Aventis merger

| 9 months 2004 (adjusted) | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|---------------|---------------|---------------|--------------|-----------------|---------------|
| Non-Group sales | 10,853 | 62,725 | 14,797 | 25 | | 88,400 |
| Intersegment sales | 10,416 | 2,034 | 511 | 128 | (13,089) | - |
| Excise taxes | | (17,559) | | | | (17,559) |
| Revenues from sales | 21,269 | 47,200 | 15,308 | 153 | (13,089) | 70,841 |
| Operating expenses | (9,409) | (44,434) | (14,027) | (380) | 13,089 | (55,161) |
| Depreciation, depletion, and amortization of tangible assets | (2,444) | (744) | (612) | (26) | | (3,826) |
| Operating income | 9,416 | 2,022 | 669 | (253) | | 11,854 |
| Equity in income (loss) of affiliates and other items | 394 | 96 | 9 | 502 | | 1,001 |
| Tax on net operating income | (5,356) | (625) | (211) | 95 | | (6,097) |
| Net operating income | 4,454 | 1,493 | 467 | 344 | | 6,758 |
| Net cost of net debt | | | | | | (72) |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | | | | | | (190) |
| Net income | | | | | | 6,496 |

| 9 months 2004 | Upstream | Downstream | Chemicals | Corporate | Intercompany | Total |
|---|----------|------------|-----------|-----------|--------------|--------|
| Total expenditures | 3,933 | 951 | 645 | 46 | | 5,575 |
| Divestitures at selling price | 315 | 127 | 68 | 28 | | 538 |
| Cash flow from operating activities (3) | 7,248 | 3,009 | 262 | 321 | | 10,840 |

(3) In the Chemicals segment, this figure amounts to 549 million euros excluding 287 million euros paid relating to the Toulouse AZF plant explosion.

CONSOLIDATED STATEMENT OF INCOME (Impact of adjustments)

Total

(unaudited)

| Amounts in millions of euros | 9 months 2005 | | | 9 months 2004 |
|---|------------------|--------------|-------------------------------------|------------------|
| | Adjusted | Adjustments | Consolidated statement of income | Adjusted |
| Sales | 103,226 | - | 103,226 | 88,400 |
| Excise taxes | (15,503) | - | (15,503) | (17,559) |
| Revenues from sales | 87,723 | - | 87,723 | 70,841 |
| Purchases, net of inventory variation | (52,053) | 2,179 | (49,874) | (40,995) |
| Other operating expenses | (14,543) | (9) | (14,552) | (13,903) |
| Unsuccessful exploration costs | (277) | - | (277) | (263) |
| Depreciation, depletion, and amortization of tangible assets | (3,765) | (11) | (3,776) | (3,826) |
| Operating income | | | - | - |
| Corporate | (254) | - | (254) | (253) |
| Business segments | 17,339 | 2,159 | 19,498 | 12,107 |
| Total operating income | 17,085 | 2,159 | 19,244 | 11,854 |
| Other income | 73 | - | 73 | 146 |
| Other expense | (98) | (144) | (242) | (322) |
| Financial charge on debt | (875) | - | (875) | (535) |
| Financial income on cash and cash equivalents and equity securities | 658 | - | 658 | 431 |
| Cost of net debt | (217) | - | (217) | (104) |
| Other financial income | 304 | - | 304 | 281 |
| Other financial expense | (202) | - | (202) | (158) |
| Income taxes | (8,991) | (664) | (9,655) | (6,065) |
| Equity in income (loss) of affiliates | 1,258 | (361) | 897 | 1,054 |
| Consolidated net income | 9,212 | 990 | 10,202 | 6,686 |
| Group share | 8,951 | 981 | 9,932 | 6,496 |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | 261 | 9 | 270 | 190 |

| Amounts in millions of euros | 3 rd quarter 2005 | | | 3 rd quarter 2004 |
|---|---------------------------------|--------------|-------------------------------------|---------------------------------|
| | Adjusted | Adjustments | Consolidated statement of income | Adjusted |
| Sales | 38,414 | - | 38,414 | 32,296 |
| Excise taxes | (5,206) | - | (5,206) | (6,925) |
| Revenues from sales | 33,208 | - | 33,208 | 25,371 |
| Purchases, net of inventory variation | (21,154) | 1,066 | (20,088) | (15,279) |
| Other operating expenses | (4,407) | (9) | (4,416) | (4,240) |
| Unsuccessful exploration costs | (113) | - | (113) | (81) |
| Depreciation, depletion, and amortization of tangible assets | (1,277) | - | (1,277) | (1,324) |
| Operating income | | | - | - |
| Corporate | (89) | - | (89) | (51) |
| Business segments | 6,346 | 1,057 | 7,403 | 4,498 |
| Total operating income | 6,257 | 1,057 | 7,314 | 4,447 |
| Other income | 31 | - | 31 | - |
| Other expense | (56) | (7) | (63) | (129) |
| Financial charge on debt | (324) | - | (324) | (171) |
| Financial income on cash and cash equivalents and equity securities | 257 | - | 257 | 145 |
| Cost of net debt | (67) | - | (67) | (26) |
| Other financial income | 100 | - | 100 | 92 |
| Other financial expense | (79) | - | (79) | (54) |
| Income taxes | (3,421) | (347) | (3,768) | (2,328) |
| Equity in income (loss) of affiliates | 461 | (180) | 281 | 433 |
| Consolidated net income | 3,226 | 523 | 3,749 | 2,435 |
| Group share | 3,126 | 519 | 3,645 | 2,365 |
| Minority interests and dividends on subsidiaries' redeemable preferred shares | 100 | 4 | 104 | 70 |